A Phase 1b/2 Single and Multiple Dose Study to Assess the Safety, Tolerability, Clinical Activity, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of STAR-0215 in Participants with Hereditary Angioedema (The ALPHA-STAR Trial)
CompletedCTIS2022-502953-32-01
Astria Therapeutics Inc.Hereditary Angioedema (HAE)
Start: 2024-04-02End: 2025-03-13Target: 25Updated: 2025-03-18